Close Menu

NEW YORK (360Dx) – French specialty diagnostics firm Sebia said this week that the US Food and Drug Administration has cleared the company's Hydrashift 2/4 daratumumab assay for evaluating multiple myeloma patients treated with Darzalex (daratumumab).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.